Journal
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
Volume 262, Issue -, Pages S79-S83Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00406-012-0354-3
Keywords
Schizophrenia; Blood test; Diagnosis; Personalised medicine
Categories
Funding
- Stanley Medical Research Institute (SMRI)
- Psynova Neurotech
- European Union [223427]
- Dutch Fund for Economic Structure Reinforcement [0908]
- German Association for Psychiatry and Psychotherapy (DGPPN)
Ask authors/readers for more resources
Schizophrenia is a complex disease with mostly unknown aetiology. Rapid development of molecular profiling technologies in recent years has facilitated identification of physiological processes associated with schizophrenia. In particular, changes have been found in the blood of schizophrenia patients, and this offers an accessible and efficient alternative to brain samples for research purposes. Here, we review the metabolic, immune and hormonal imbalances characterised in subgroups of schizophrenia patients and discuss potential applications in differential diagnosis, prognosis and early intervention. We also describe development of the first validated biological blood test for diagnosis of schizophrenia, and the challenges involved after introduction of this into clinical practice. Moreover, we discuss possibilities for further research on biomarkers for diagnostic applications in schizophrenia. Promising research avenues include extension to functional analysis of blood cells and applications in prediction of drug response and novel drug discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available